指南与共识骨肌儿科影像技术与安全

亚太抗风湿病联盟关于幼年特发性关节炎管理的共识推荐:多关节型JIA、颞下颌关节炎、影像学及非药物治疗

The Asia-Pacific League of Associations for Rheumatology Consensus Recommendations on the Management of Juvenile Idiopathic Arthritis (JIA): Polyarticular Course JIA, Temporomandibular Joint Arthritis, Imaging, and Non-Pharmacologic Therapies.
指南 / 共识 · Int J Rheum Dis · 2026-01-01

亚太抗风湿病联盟组织34名多学科成员,采用GRADE、ADAPTE和AGREE II框架,系统评价文献并回答26个PICO问题,经改良Delphi投票(共识≥80%一致)最终形成4项总体原则和32条推荐,涵盖多关节型JIA治疗、颞下颌关节炎、非药物治疗、影像学和疾病监测,提出与西方指南不同的区域化推荐。

要点

  • 影像学相关推荐共2条,强调影像在JIA评估中的作用,具体条款见推荐原文。
  • 甲氨蝶呤作为初始治疗先于生物制剂DMARDs获得更强推荐。
  • 强调以cJADAS-10进行达标治疗,并更强推荐物理治疗和作业治疗。

核心结论

  • 这些共识声明提供区域适应的循证推荐,以改善亚太地区JIA患者的可及性、标准化管理并促进公平医疗。

研究设计与样本

  • 由14个国家34名成员组成的多学科工作组制定,采用GRADE、ADAPTE和AGREE II框架,系统评价国际指南与文献,回答26个PICO问题,经改良Delphi投票,共识定义为≥80%一致。

诊断标准与关键数值

  • 共4项总体原则和32条声明:16条用于pcJIA治疗,10条用于颞下颌关节炎,3条用于非药物治疗,2条用于影像学,1条用于疾病监测。
  • 共识定义:改良Delphi投票≥80%一致。
  • 影像学推荐共2条,原文未给出具体推荐等级、敏感度、特异度、AUC或阈值。

临床应用与阅片要点

  • 甲氨蝶呤作为初始治疗先于生物制剂DMARDs获得更强推荐。
  • 当需要升级治疗时,明确倡导使用TNF抑制剂(包括生物类似药)。
  • 在DMARDs可及性有限时,谨慎允许短期全身性糖皮质激素使用。
  • 强调使用cJADAS-10进行达标治疗。
  • 更强推荐物理治疗和作业治疗;在专业监督下条件性允许传统和补充医学实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Juvenile idiopathic arthritis (JIA) is one of the most common childhood rheumatic diseases. In the Asia-Pacific region, access to pediatric rheumatology services and therapies remains variable. To address regional disparities and promote evidence-based yet practical care, the APLAR developed consensus recommendations for the management of polyarticular-course JIA (pcJIA), temporomandibular joint (TMJ) arthritis, and non-pharmacologic interventions.

METHODS: A multidisciplinary task force of 34 members from 14 countries, including pediatric and adult rheumatologists and patient representatives, was convened. The guideline development followed the GRADE, ADAPTE, and AGREE II frameworks. Existing international guidelines were critically appraised, and a systematic literature review was performed to address 26 PICO questions. Draft statements were discussed and voted upon using a modified Delphi process, with consensus defined as ≥ 80% agreement.

RESULTS: Four overarching principles and 32 statements were finalized: 16 for pcJIA treatment, 10 for TMJ arthritis, 3 for non-pharmacologic therapies, 2 for imaging, and 1 for disease monitoring. Key recommendations that diverge from Western guidelines include: (1) stronger recommendation for methotrexate as initial therapy before biologic DMARDs; (2) explicit advocacy for TNF inhibitors, including biosimilars, when escalation is required; (3) cautious allowance of short-term systemic glucocorticoids where DMARDs are limited; (4) emphasis on treat-to-target using cJADAS-10; (5) stronger endorsement for physical and occupational therapy; and (6) conditional allowance of traditional and complementary medicine practices under professional supervision.

CONCLUSION: These consensus statements provide regionally adapted, evidence-based recommendations to improve access, standardize management, and promote equitable care for patients with JIA across the Asia-Pacific region.

来源:Int J Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Arkachaisri T, Teh KL, Vilaiyuk S, et al. The Asia-Pacific League of Associations for Rheumatology Consensus Recommendations on the Management of Juvenile Idiopathic Arthritis (JIA): Polyarticular Course JIA, Temporomandibular Joint Arthritis, Imaging, and Non-Pharmacologic Therapies. Int J Rheum Dis. 2026. PMID: 41974617. doi:10.1111/1756-185x.70640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。